GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00335235 | Skin | cSCC | histone H2B ubiquitination | 11/4864 | 12/18723 | 3.30e-06 | 5.08e-05 | 11 |
GO:001657415 | Skin | cSCC | histone ubiquitination | 27/4864 | 47/18723 | 4.79e-06 | 7.03e-05 | 27 |
GO:00063603 | Skin | cSCC | transcription by RNA polymerase I | 30/4864 | 55/18723 | 6.13e-06 | 8.70e-05 | 30 |
GO:006145825 | Skin | cSCC | reproductive system development | 149/4864 | 427/18723 | 2.30e-05 | 2.65e-04 | 149 |
GO:004860824 | Skin | cSCC | reproductive structure development | 148/4864 | 424/18723 | 2.40e-05 | 2.74e-04 | 148 |
GO:00459433 | Skin | cSCC | positive regulation of transcription by RNA polymerase I | 15/4864 | 23/18723 | 8.72e-05 | 8.21e-04 | 15 |
GO:000182512 | Skin | cSCC | blastocyst formation | 21/4864 | 38/18723 | 1.17e-04 | 1.08e-03 | 21 |
GO:00063025 | Skin | cSCC | double-strand break repair | 89/4864 | 251/18723 | 5.23e-04 | 3.92e-03 | 89 |
GO:20002341 | Skin | cSCC | positive regulation of rRNA processing | 8/4864 | 10/18723 | 5.51e-04 | 4.04e-03 | 8 |
GO:005067324 | Skin | cSCC | epithelial cell proliferation | 144/4864 | 437/18723 | 6.07e-04 | 4.38e-03 | 144 |
GO:006074212 | Skin | cSCC | epithelial cell differentiation involved in prostate gland development | 7/4864 | 11/18723 | 9.45e-03 | 4.25e-02 | 7 |
GO:2000232 | Skin | cSCC | regulation of rRNA processing | 9/4864 | 16/18723 | 9.73e-03 | 4.31e-02 | 9 |
GO:007265927 | Thyroid | HT | protein localization to plasma membrane | 36/1272 | 284/18723 | 2.24e-04 | 3.20e-03 | 36 |
GO:199077825 | Thyroid | HT | protein localization to cell periphery | 39/1272 | 333/18723 | 6.29e-04 | 7.21e-03 | 39 |
GO:002241123 | Thyroid | HT | cellular component disassembly | 47/1272 | 443/18723 | 1.60e-03 | 1.48e-02 | 47 |
GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
GO:0042254113 | Thyroid | PTC | ribosome biogenesis | 202/5968 | 299/18723 | 3.47e-37 | 5.47e-34 | 202 |
GO:0006364112 | Thyroid | PTC | rRNA processing | 156/5968 | 225/18723 | 5.58e-31 | 5.03e-28 | 156 |
GO:0016072112 | Thyroid | PTC | rRNA metabolic process | 160/5968 | 236/18723 | 5.68e-30 | 3.58e-27 | 160 |
GO:1903320113 | Thyroid | PTC | regulation of protein modification by small protein conjugation or removal | 148/5968 | 242/18723 | 4.49e-21 | 8.10e-19 | 148 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WDR7 | SNV | Missense_Mutation | | c.2250N>G | p.Ile750Met | p.I750M | Q9Y4E6 | protein_coding | tolerated(0.19) | benign(0.015) | TCGA-A1-A0SH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD |
WDR7 | SNV | Missense_Mutation | | c.2882C>G | p.Ala961Gly | p.A961G | Q9Y4E6 | protein_coding | tolerated(0.06) | benign(0.017) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
WDR7 | SNV | Missense_Mutation | rs778537690 | c.1597N>G | p.Ile533Val | p.I533V | Q9Y4E6 | protein_coding | tolerated(0.52) | benign(0) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
WDR7 | SNV | Missense_Mutation | | c.686N>T | p.Ser229Leu | p.S229L | Q9Y4E6 | protein_coding | deleterious(0.04) | benign(0.023) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
WDR7 | SNV | Missense_Mutation | | c.3245G>C | p.Gly1082Ala | p.G1082A | Q9Y4E6 | protein_coding | tolerated(0.32) | benign(0.024) | TCGA-A8-A07B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WDR7 | SNV | Missense_Mutation | novel | c.1208G>T | p.Ser403Ile | p.S403I | Q9Y4E6 | protein_coding | tolerated(0.16) | benign(0) | TCGA-AR-A24U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
WDR7 | SNV | Missense_Mutation | | c.1616A>T | p.Asp539Val | p.D539V | Q9Y4E6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B6-A0RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
WDR7 | SNV | Missense_Mutation | | c.1195G>T | p.Val399Leu | p.V399L | Q9Y4E6 | protein_coding | tolerated(0.78) | benign(0) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
WDR7 | SNV | Missense_Mutation | novel | c.2219N>T | p.Ala740Val | p.A740V | Q9Y4E6 | protein_coding | tolerated(0.13) | benign(0.021) | TCGA-C8-A8HR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
WDR7 | SNV | Missense_Mutation | | c.1991G>C | p.Gly664Ala | p.G664A | Q9Y4E6 | protein_coding | tolerated(0.12) | possibly_damaging(0.775) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD |